Redefining what’s possible in cystic fibrosis treatment

Our vision is to fully normalize CFTR function

More

Pipeline

We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function.

Discovery
Pre-Clinical
IND-Enabling
Phase 1
NBD1
SION-638
IND-Enabling
NBD1
Additional candidates
Pre-Clinical
ICL4
SION-109
IND-Enabling
ICL4
Additional Candidates
Pre-Clinical
TMD1
Candidates
Pre-Clinical

Every day I get to go to work and interact with an awesome group of people. Even cooler than that, we all do work that will positively impact patients’ lives!

Direct…but from every conceivable angle! That’s how I would describe the drug discovery strategy at Sionna. I am grateful for the opportunity to work toward the goal of normal CFTR function for CF patients.